AphioTx is excited to announce we have been chosen to advance to the top 10 at Start Up TNT’s Life Sciences Investment Summit. Watch the recording of our pitch that landed us the next spot in the summit.
Over a 15-year period, key scientific discoveries were made that changed our understanding of the important roles pannexin-1 channels play in opioid withdrawal, chronic pain, stroke, and cognitive impairment. These discoveries were led by three researchers from the Hotchkiss Brain Institute at the University of Calgary: Drs. Tuan Trang, Roger Thompson, and Darren Derksen.
The CIHR Project Grant program chose projects led by Drs. Sabine Gilch, PhD, Tuan Trang, PhD, and Patrick Whelan, PhD, all researchers in the University of Calgary Faculty of Veterinary Medicine (UCVM).
Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary’s Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) at the Cumming School of Medicine (CSM) have discovered that an existing anti-gout medication is effective in reducing the severity of withdrawal symptoms in opioid-dependent rodents.
Opioids are the mainstay of treatment strategies to reduce pain, but withdrawal can be a serious problem when patients stop taking these drugs. However, beyond the recognition that microglia play a role in this phenomenon, little is known about the cellular mechanisms involved. Now, new research shows how microglia contribute to withdrawal in rodents and identifies a potential path toward easing withdrawal in patients.
Originally published by The Globe and Mail on January 30, 2017 Researchers in Alberta have discovered that a medication once used to treat gout is effective in reducing withdrawal symptoms in opioid-dependent rodents, raising the possibility it could one day do the same for humans. The researchers, from the University Read more…
Drug eases withdrawal symptoms in rodents, human trials next Originally published by CBC News on January 30, 2017 University of Calgary researchers believe a medication already being used to treat gout could be a weapon in the fight against opioid dependency — by alleviating withdrawal symptoms. “It’s quite effective [on Read more…
